Fibronectin based scaffold domain proteins that bind PCSK9
US-10947297-B2 · Mar 16, 2021 · US
Fibronectin based scaffold domain proteins that bind PCSK9
US11858979B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11858979-B2 |
| Application number | US-202117177179-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 16, 2021 |
| Priority date | Apr 13, 2010 |
| Publication date | Jan 2, 2024 |
| Grant date | Jan 2, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
First claim
Opening claim text (preview).
We claim: 1. An isolated nucleic acid molecule encoding a polypeptide comprising a fibronectin type III tenth ( 10 Fn3) domain wherein the 10 Fn3 has a BC, DE and FG loop, and wherein the BC loop comprises SEQ ID NO:14, the DE comprises SEQ ID NO:25 and the FG loop comprises SEQ ID NO:37, and wherein the polypeptide binds PCSK9. 2. The isolated nucleic acid molecule of claim 1 , wherein the BC loop comprises nucleotides 67-96 of SEQ ID NO:83, the DE loop comprises nucleotides 157-174 of SEQ ID NO:83 and the FO loop comprises nucleotides 232-270 of SEQ 1D NO:83. 3. An isolated nucleic acid molecule encoding a polypeptide comprising a 10 Fn3 domain wherein the polypeptide comprises SEQ ID NO:82, and wherein the polypeptide binds PCSK9. 4. The isolated nucleic acid molecule of claim 3 , wherein the isolated nucleic acid molecule comprises SEQ ID NO:83. 5. An expression vector comprising the isolated nucleic acid sequence of claim 1 . 6. An expression vector comprising the isolated nucleic acid sequence of claim 3 . 7. A cell comprising the isolated nucleic acid sequence of claim 1 . 8. A cell comprising the isolated nucleic acid sequence of claim 3 . 9. A method of producing a PCSK9-binding polypeptide comprising culturing the cell of claim 7 under conditions suitable for expressing the polypeptide and purifying the polypeptide. 10. A method of producing a PCSK9-binding polypeptide comprising culturing the cell of claim 8 under conditions suitable for expressing the polypeptide and purifying the polypeptide.
Assignees
Inventors
Classifications
- C07K14/78Primary
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] · CPC title
Sugars, nucleosides, nucleotides or nucleic acids · CPC title
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
against material from animals or humans · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11858979B2 cover?
- The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof…
- Who is the assignee on this patent?
- Bristol Myers Squibb Co, Bristol Meyers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification C07K14/78. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).